Europe to Accelerate Review of RevMed Drug

European regulatory authorities plan to accelerate their assessment of a drug developed by RevMed, according to a report from STAT News. Details on the specific mechanism or indication were not provided. The expedited timeline was one of several brief updates on biotech developments.

Other updates from the sector

The same report noted that data for a GLP-1 pill from Kailera raised concerns. The nature of these concerns was not detailed. In a separate action, the FDA cleared an autoimmune therapy from Vera.